MAZE CEO Jason Coloma Sells Shares in Planned Transaction
Jason Coloma, CEO of MAZE, sold 3,993 shares in a planned transaction on June 22, 2026.
Key Points
- Jason Coloma, CEO of MAZE, sold 3,993 shares valued at $103,818 on June 22, 2026, as part of a planned transaction.
- MAZE shares traded near $26.67 on Thursday, with analysts maintaining a 'buy' rating and setting price targets up to $110.
- Institutional peers like Deep Track Capital reduced holdings by 768,878 shares, while Paradigm Biocapital Advisors opened a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jason Coloma, the Chief Executive Officer of MAZE, sold 3,993 shares of the company in a planned transaction on June 22, 2026. The shares were sold at an average price of $26.00, totaling $103,818. This transaction was part of a Rule 10b5-1 trading plan, which allows company insiders to sell a predetermined number of shares at a set time.
Insider Buying and Selling at Maze Therapeutics, Inc.
On June 23, 2026, Jason Coloma also sold an additional 23,865 shares at $26.05 each, further executing his planned sales. Other insiders, including Charles Homcy, Daniel Spiegelman, Jonathan Lim, and Nancy Andrews, each acquired 18,000 shares on June 8, 2026, as unplanned purchases.
Other Institutional Activity in MAZE
Frazier Life Sciences Management, L.P. held steady with 4,567,274 shares valued at approximately $136.3 million. TRV GP IV, LLC also maintained its position with 4,473,958 shares worth about $133.5 million. Meanwhile, Deep Track Capital, LP reduced its holdings by 768,878 shares, now holding 3,477,562 shares valued at $103.8 million, an 18.1% decrease. Janus Henderson Group PLC cut its stake by 283,711 shares, leaving it with 2,858,876 shares worth $85.3 million, a 9% reduction. Paradigm Biocapital Advisors LP opened a new position with 2,744,399 shares valued at $81.9 million.
Analysts Set New Price Targets
Analysts have been active in setting price targets for MAZE, with Truist Securities maintaining a 'buy' rating and a price target of $64 on April 14, 2026. JP Morgan also maintained a 'buy' rating with a target of $58 on March 31, 2026. HC Wainwright & Co. set a higher target of $110 on March 25, 2026, maintaining their 'buy' stance. The consensus among analysts remains positive, with a 'buy' recommendation and an average price target reflecting strong growth potential.
Bottom Line
Jason Coloma's planned sale of shares reflects a strategic move under a trading plan, and it does not necessarily indicate a lack of confidence in MAZE. The company's stock continues to be viewed positively by analysts, with multiple 'buy' ratings and ambitious price targets. As always with insider transactions, it's important to consider the broader context and other factors influencing the company's performance.
Get Maze Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MAZE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.